Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Clinical trial NCT03890289 · TERMINATED

Trial details

NCT number: NCT03890289
Sponsor: Fondazione Italiana Linfomi - ETS
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Follicular Lymphoma

Start date: 2019-10-18
Primary completion: 2021-04-29
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.